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Abstract
Background: One of the most commonly applied protectotype vaccination protocol against infectious bronchitis
(IB) in broiler chickens in the EU is simultaneous or alternate use of Ma5 and 4/91 vaccine strains. After IB vaccination
and infection, systemic and upper respiratory tract (URT), humoral and cell-mediated immunity (CMI), are stimulated.
The level of this stimulation correlates with the level of protection against IB.
Results: We’ve investigated the development of URT and systemic, cell-mediated and humoral immunity in commercial
broiler chickens vaccinated with Ma5 and/or 4/91 strains at hatch day. We’ve demonstrated that the group vaccinated
with Ma5 and 4/91 strain simultaneously developed the most desirable immunity which reflects the level of CD8+ T cells
stimulation in spleen and Harderian gland, as well as the level of IgA and IgY in URT washings and serum and
their cross-reactivity with 7 IBV strains.
Conclusions: Although we did not demonstrate directly why Ma5 + 4/91 protocol is so efficient it seems that it
combines the benefits of monovalent vaccination with either Ma5 or 4/91 and while Ma5 seems to stimulate CMI
more efficiently, the 4/91 strain generates a wider spectrum of immune system cross-reactivity and higher URT
IgA production.
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Background
Infectious bronchitis (IB) is a highly contagious viral dis-
ease of chickens. IBV frequently changes its genotype
and antigenic properties, tissue tropism, pathogenicity
and eventually the course of the disease [1]. Due to the
high level of antigenic variation among circulating vi-
ruses, establishing an effective vaccination schedule
against IB has been difficult [1]. On the other hand, simul-
taneous or alternate use of Ma5 and 4/91, as commonly
employed in the EU, induces high levels of protection
against heterologous IBV types such as D1466 or QX. It
has been demonstrated that this protocol doesn’t influ-
ence the development of protection against homologous
IBVs while inducing high protection against heterologous
IBV types such as D1466 or QX [2, 3].
After IB vaccination and infection, systemic and upper
respiratory tract (URT), humoral and cell-mediated im-
munity (CMI), are stimulated. IBV are highly immuno-
genic and stimulate production of antibodies which can
be detected with enzyme-linked immunosorbent assay
(ELISA), serum neutralisation (SN) or haemaglutination
inhibition (HI) test [2, 4, 5]. Although, humoral immun-
ity can’t be considered a direct correlate of upper re-
spiratory tract protection against IB, since the level of
Igs in tears were not in correlation with the resistance to
respiratory challenge, specific antibodies inhibit IBV rep-
lication in structures other than URT [1, 6–8].
Systemic CMI is considered as a decisive factor in pro-
tection against IB. Activation of cytotoxic cells correlated
with lung and kidney IBV clearance [1]. Pei et al. [9]
demonstrated that CD8+T cells isolated from spleens of
birds, that recovered from IB and used for immuno-
logical transfer to naive chicks were capable of alleviating
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Little is known about the role of URT immunity in the
protection against IBV. Several investigations indicated
the role of innate immunity in the URT in the course of
IB. Those mechanisms are not able to cure the infection,
but they limit IBV replication and initiate specific im-
munity stimulation [10–12]. CD8+ T cells, capable of
eliminating virus-infected cells, are mainly involved in
the early stages of IB [5, 13] while CD4+ T cells and B
lymphocytes are involved in later stages of specific im-
munity development [1, 4].
Considering the above, our own research was carried
out in order to determine the development of URT and
systemic, cell-mediated and humoral immunity following
simultaneous immunization with the heterologous Ma5
and 4/91 IBV strains in commercial broiler chickens vac-
cinated at hatch day.
Methods
The experimental procedures and animal handling pro-
cedures were conducted with the approval of the Local
Ethics Committee for Animal Experiments in Olsztyn,
Poland (approval number: 12/2015).
Birds and vaccines
Experiments were conducted on 327 1-day old Ross 308
broiler chickens purchased from a commercial hatchery.
Chickens were vaccinated in-ovo against Marek’s disease
with bivalent (HVT + Rispens) vaccine. No additional vac-
cinations were performed at the hatchery. On day one
blood samples and tracheal washings (TW) were collected
from 23 randomly selected birds in order to establish the
level of anti-IBV maternally derived antibodies (MDA).
The rest of the birds were divided into 4 group (76 birds
per group) as follows: control was the group that was not
vaccinated against IB, Ma5 was the group vaccinated
against IB at 1st day of life (dol) with the use of Ma5 strain,
4/91 group was vaccinated at 1st dol with 4/91 strain and
V2 group was vaccinated at 1st dol with both Ma5 and 4/
91 strain in one diluent (sterile distilled water). Vaccin-
ation protocol was identical to the one described previ-
ously by Cook et al. [1] who (in one of the performed
experiments) vaccinated SPF chickens with Ma5 and 4/91
strains at 1st dol. All vaccines were prepared according to
manufacturer instructions (Merck Animal Health, USA)
and the birds were vaccinated oculo-nasally in a dose rec-
ommended by the manufacturer. Control group received
sterile vaccine diluent at 1st dol oculo-nasally.
Birds were raised till 21 dol in isolated units main-
tained at PCL 3 (physical containment level 3) facility.
Water and feed were given to birds ad libitum.
Experimental design
Birds were raised till 21 dol and during that period fol-
lowing samples were collected from birds of all of the
experimental groups for laboratory evaluation. On 3, 7
and 14 days post vaccination (DPV) 5 samples of HGs
(entire organ bilaterally; one sample was pooled from 3
birds, so 5 samples originated from 15 birds) and 5
spleen samples (individual) were collected for flow cy-
tometry analysis of relative (in spleen; relative cell
count—RCC) or absolute (in HG, absolute cell coun-
t—ACC) counts of CD4+ and CD8+ T as well as Bu1A+
B cells. Twenty three blood samples were collected at 14
and 21 DPV for serological evaluation of anti-IBV IgY in
the serum. at 7, 14 and 21 DPV 15 samples of tracheal
washings were collected for serological evaluation of
specific anti-IBV IgY and IgA levels. Tracheal washings
were collected by passing 1 ml of phosphate-buffered sa-
line (PBS, pH 7.2, Sigma Aldrich, Germany) through the
lumen of the trachea with a 2 ml syringe. The trachea
was massaged gently to intensify the washing effect. TW
and serum samples were stored at −20 °C until further
analysis. Additionally, 5 serum samples reacting positive
in ELISA at 21 DPV were subjected for HI analysis of
cross-reactivity with different IBV diagnostic strains. Ex-
perimental design is summarized in Table 1.
Flow cytometry
Isolation of mononuclear cells from HGs and spleens were
performed as described previously [14]. HG and spleen
samples (0,3 g +/− 10%) were homogenized in a manual
Dounce tissue grinder and filtered (70 μm mesh). Cells
pellets, obtained after centrifugation (450 g for 10 min at
20 °C), were resuspended in 3 ml of 40% Percoll density
gradient and gently layered on 3 ml of 60% Percoll. Mono-
nuclear cells were collected from the interphase after
density centrifugation (20 min, 1900 g, 20 °C). Finally, the
obtained mononuclear cells were resuspended in 1 ml of
PBS. Vi-cell XR (Beckman Coulter, USA) cell counter and
cell viability analyzer was used for each sample to calcu-
late the absolute lymphocyte counts (ALC) per ml.
Half million (from HG) or 1 × 106 (from spleens) of
viable mononuclear cells were stained (3 μl/1 × 106 cells)
with monoclonal mouse anti-Chicken CD4 FITC
(0,1 mg/ml) and mouse anti-chicken CD8 RPE (0,1 mg/ml)
or mouse anti-chicken Bu1a FITC (0,1 mg/ml) antibodies
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On different DPV, samples were collected simultaneously from all of the
experimental groups
a21 DPV 5 serum samples reacting possitive in ELISA were subjected for
HI evaluation
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(AbD Serotec, UK), incubated for 30 min on ice, washed
twice in PBS and analyzed with the FACSCanto II (BD,
USA) flow cytometer.
Further steps of flow cytometry data acquisition and
dual platform analysis allowing the calculation of CD4+
and CD8+ T and Bu1a+ B RCC in the spleen and CD4+,
CD8+ T and Bu1a+ B ACC in HG samples were performed
as described previously [14]. ACC of T and B cells for HG
samples were calculated with the use of the following for-
mula: ACC = (ALC * RCC)/100%. Data were expressed as
mean RCC (for spleen samples) or ACC (for HG samples)
of different T or B cell subpopulations +/− SD.
ELISA
ELISA evaluation was performed with the use of commer-
cial IBV ELISA kit (IDEXX, USA) according to manufac-
turer recommendation with minor modifications. Serum
samples collected from birds 14 and 21 DPV were diluted
1:100 (instead of 1:500) in order to increase low antibody
level detection. TW were tested undiluted and the level of
specific IgA in TW was detected as described previously
[15] with minor modifications. Anti-IBV IgA antibodies
were detected by replacing the conjugated antibodies of
ELISA kit with goat anti-chicken IgA HRP antibodies (AbD
Serotec, UK) dilluted 1:10 000. The following steps of
ELISA procedure were performed with Eppendorf epMo-
tion 5075 LH automated pipetting station (Eppendorf,
Germany), BioTek ELx405 automatic plate washer (BioTek,
USA) and BioTek ELx800 plate reader. Based on sample
ODs the sample to positive (S/P)-ratios were calculated and
used to express the mean serum and TW anti-IBV antibody
(S/P)-ratio +/− SD per group and day post vaccination.
Mean OD values +/− SD per group and day post vaccin-
ation were used to express the level of anti-IBV IgA anti-
bodies in TW.
HI test
HI test was performed with M41, 793B, D3128, Italy O2,
D8880, D274, D1466 HA antigens obtained from GD
Animal Health Service (Deventer, Netherlands). The HI
test was conducted according to standard procedure
(OIE) using 4 HA units of antigen per well. The result of
HI analyzes are express as mean HI antibody titer (log2
base) +/− SD.
Statistical analysis
Statistical analysis of flow cytometry results was per-
formed with GraphPad Prism 6.05 with the use of stu-
dent T - test. Differences were considered statistically
significant if p < 0,05 and highly significant if p < 0,01.
Statistical analysis of serological evaluation (ELISA, HI)
results was performed with Statistica Pl v.10 with the
use of nonparametric Kruskal-Wallis test. Differences
were considered statistically significant if p < 0,05.
Results and discussion
At the beginning of the experiment chicks had high anti-
IBV MDA levels both in serum (mean S/P ratio = 2.349
+/− 1.17) and TW (mean OD= 0.203 +/− 0.452) and the
level of these antibodies declined gradually in the control
group (Fig. 3a and b). MDA have been demonstrated to
interfere with immune response after IB vaccination. For
example, Terregino et al. [3] demonstrated that commer-
cial chickens vaccinated against IB with the use of Ma5
and 4/91 strains (with 14 days interval between vaccina-
tions) developed lower titers of HI antibodies in compari-
son with SPF birds. Nevertheless, in this trial, both SPF
and commercial chickens had significantly increased HI
antibody titers in comparison with the adequate control
groups. Additionally, Chhabra et al. [16] demonstrated that
MDA do not influence the production of IgA in URT after
vaccination (with either H120 strain alone or in combin-
ation with CR88) of day old commercial broiler chickens.
In this experiment infiltration of different subpopulations
of T and B cells in the URT was also unaltered and consist-
ent with SPF birds. Overall, it seems that maternal immun-
ity, to some extent, may neutralize the vaccine virus
(especially when given to birds at the hatch day) but the
general outcome of immune system stimulation after IB
vaccination is unaltered by the MDA.
Both Ma5 and 4/91 vaccine strains belong to a differ-
ent, antigenically distinct serotypes. Ma5 is based on the
Massachusetts (Mass) serotype and the 4/91 strain be-
longs to 4/91 serotype. Wild-types of those viruses are
known for their different tissue tropism, pathogenicity
and most importantly antigenic structure. IBV serotyping
is done based on the S1 protein amino acid sequence
analysis. The basic hypothesis of protectotype vaccin-
ation strategy, presented by Cook et al. [2], was that -
new IBV serotypes can arise as a result of only a very
few changes in the amino acid composition of the S1
part of IBV spike protein. On the other hand remaining
part of the virus antigen uniform remains unchanged.
Those shared antigens can induce cross protective im-
munity against heterologous viruses. As it turned out,
the combination of Ma5 and 4/91 vaccine strains for
vaccination of chickens resulted in greater cross protec-
tion against heterologous IB viruses in comparison to
monovalent vaccination with either Ma5 or 4/91 strain
[2]. However, up to date, the underlying immune mech-
anism that could explain the efficacy of this protocol is
unknown.
Cellular immune response
Considering the fact that CMI associated mainly with
cytotoxic T cells is protective against IBV we have
performed flow cytometry analysis of both URT and
systemic cellular immune response after different IB
vaccination protocols.
Smialek et al. BMC Veterinary Research  (2017) 13:44 Page 3 of 7
Ma5 group
In the Ma5 group statistically significant increase of
CD4+ and CD8+ T ACC in HG was recorded 3 and 7
DPV (Fig. 1a and b). Additionally, in the Ma5 group sig-
nificant or highly significant increase of Bu1A+ B ACC
in HG was recorded 7 and 14 DPV (Fig. 1c) respectively
in comparison to the control group.
Statistically significant decrease of CD4+ T RCC was
recorded in the spleen 14 DPV (Fig. 2a) in the Ma5
group. Additionally in this group, significant increase of
CD8+ T RCC (Fig. 2b) in the spleen was recorded 14
DPV in comparison to the control group.
4/91 group
In 4/91 group statistically significant increase of CD4+
T ACC was recorded 3 DPV in HG (Fig. 1a). In this
group we’ve recorded a significant increase of Bu1A+
B ACC in HG 3 and 14 DPV (Fig. 1c) in comparison
to the control group.
Significant increase of CD4+ T RCC in the spleen was
recorded 3 DPV in 4/91 group (Fig. 2a). In this group
we’ve recorded a significant and highly significant in-
crease of Bu1A+ B RCC, 7 and 14 DPV (Fig. 2c), in com-
parison to the control group.
V2 group
In V2 group a highly significant increase of both CD4+
T and CD8+ T ACC as well as Bu1A+ B ACC in HG was
recorded 14 DPV (Fig. 1a, b and c).
In V2 group a highly significant increase of CD8+ T
RCC in the spleen was recorded 14 DPV (Fig. 2b). Add-
itionally, in this group a significant increase of Bu1A+ B
RCC was recorded 7 DPV in spleen (Fig. 2c).
Fig. 1 Mean CD4+ (a) and CD8+ (b) T and Bu1a+ B (c) ACC +/− SD
in HG samples in different groups and day post vaccination. * Significant
differences at different DPV (T-test, * as p< 0,05) in comparison to the
control group. ** Significant differences at different DPV (T-test,
** as p < 0,01) in comparison to the control group
Fig. 2 Mean CD4+ (a) and CD8+ (b) T and Bu1a+ B (c) RCC +/− SD in
spleen samples in different groups and day post vaccination. * Significant
differences at different DPV (T-test, * as p< 0,05) in comparison to the
control group. ** Significant differences at different DPV (T-test,
** as p < 0,01) in comparison to the control group
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From presented data it turns out that the fastest
stimulation of CMI parameters (associated with cells
harboring CD8 molecule) in HG was recorded in Ma5
group. Despite the delayed character of this stimulation
the highest infiltration of immunocompetent cells in
URT was recorded 14 DPV in V2 group. Unfortunately,
we did not perform further analyzes to determine the ac-
tual level of lymphocytes stimulation but if we consider
time dependencies of CD8 marker expression we may
distinguish early and late CMI stimulation. And while
early, probably associated mainly with the activation of
NK cells, was most prominently stimulated in Ma5
group, the late stimulation connected with cytotoxic
lymphocytes activity was strongest in V2 group.
The results of our study corroborates previous findings
of Chhabra et al. [16] who demonstrated that CD4+ and
CD8+ cells infiltration in the URT takes place in first
2 weeks after IB vaccination of day old broiler chickens
and that the overall number of infiltrating CD8+ cells is
greater in comparison to the number CD4+ cells. Add-
itionally, cited authors demonstrated that broilers with
higher number of infiltrating CD8+ cells in the URT (on
the day of IB infection) developed greater protection
against IBV challenge.
Considering time dependencies between CD4+ T cells
and B cells contribution in HG we may speculate that
mainly Th2 subpopulation (involved in humoral immun-
ity stimulation through cytokines production) of T
helper cells was stimulated after IB vaccination.
Similar time dependencies between CD4+ T cells and B
cells was also recorded in the spleens of vaccinated birds.
The strongest stimulation of those parameters was re-
corded in 4/91 group but also V2 which may have influ-
enced the results of HI test which will be discussed later.
The contribution of T CD8+ cells in the spleen in-
creased in all of the IB vaccinated groups (significant in-
crease was recorded in Ma5 and V2 group), but the
strongest stimulation of this parameter was recorded in
V2 group. Pei et al. [9] demonstrated that CD8+ T cells
isolated from spleens of birds, that recovered from IB
and used for immunological transfer to naive chicks
were capable of alleviating IB clinical course.
Humoral immune response
A statistically significant increase of serum IgY level was
recorded in all of the vaccinated group (in comparison
to the control group) 21 DPV while the highest mean
level of anti-IBV IgY was recorded, at this time, in V2
group (Fig. 3a).
Similarly, a statistically significant increase of mean
TW IgY level was recorded in all of the vaccinated
group (in comparison to the control group) 14 and 21
DPV, while the highest mean level of anti-IBV IgY 21
DPV was recorded in Ma5 group (Fig. 3b).
In Ma5 group a significant increase of specific IgA
mean levels was recorded 7 and 14 DPV (in comparison
to the control group). In comparison, in 4/91 and V2
group an increase anti-IBV IgA in TW was recorded 14
and 21 DPV while the highest mean level of anti-IBV
IgA 21 DPV was recorded in V2 group (Fig. 3c).
Okino et al. [4] demonstrated a gradual increase of spe-
cific IgA and IgG in the URT washings with simultaneous
activation of CMI parameters in the URT after single full-
dose vaccination of newly hatched chicks with H-120 IBV
strain. In addition, these humoral and CMI response eval-
uated at mucosal sites correlated significantly with tra-
cheal protection against homologous IBV challenge.
Additionally, our findings demonstrate that there are dif-
ferent patterns of IgA levels in tracheal washes after differ-
ent IB vaccination protocol application, which indicates
Fig. 3 Mean IgY serum level (a - data expressed as mean S/P), IgY
TW level (b - data expressed as mean S/P) and IgA TW level (c - data
expressed as mean OD) in different groups and day post vaccination.
* Significant differences at different DPV (Kruskal-Wallis test, * as p< 0,05)
in comparison to the control group
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that 4/91 strain alone or in combination with Ma5 strain
(V2 group) generates longer lasting and higher IgA levels
in TW.
HI test results are summarized in Table 2. In Ma5
group no statistical differences was recorded in mean HI
antibody titer against any of the homologous or heterol-
ogous IBV strains in comparison to the control group. In
4/91 group a statistically significant increase of mean HI
antibody titer against 5 out of 7 IBV strains (without It-
O2 and D8880) was recorded while in two cases (against
4/91 and D3128 strains) it was also significantly higher
in comparison to Ma5 group. In V2 group a statistically
significant increase of mean HI antibody titer against
D8880 IBV strain was recorded in comparison to the
control group.
Overall percentage of samples reacting positive
(neg/pos cut-off > 3 log2 HI titer) with different IBV
strains was 38.71, 77.42 and 59.38% in Ma5, 4/91 and
V2 group, respectively.
Conclusions
It has been demonstrated previously that Ma5 + 4/91 IB
vaccination protocol doesn’t influence the development
of protection against homologous IBV strains (Ma5 or 4/
91) while inducing high protection against heterologous
IBV types [2, 3]. Although 14 days interval between Ma5
(1 dol) and 4/91 (14 dol) vaccination protocol results in
even better protection (especially against heterologous
IBV types) than Ma5 and 4/91 vaccines given to birds
simultaneously at 1 dol [2], we’ve decided to use this
protocol in order to: (1) uniform birds’ age within the
experimental groups and to (2) imitate the widespread
use of this protocol under field conditions. It has been
demonstrated that both vaccination protocols (Ma5 + 4/
91 at 1st dol or Ma5 at 1st dol and 4/91 at 14th dol)
generates comparable protection against experimental
infection with either homo- or heterologous IBV sero-
type and in both cases the level of protection was greater
and wider against heterologous IBV strains in compari-
son to Ma5 or 4/91 alone vaccination protocol [2].
The aim of our study was to evaluate the immune
mechanisms that could explain the efficiency of Ma5 +
4/91 vaccination protocol. From our research it seems
that this protocol combines the benefits of monovalent
vaccination with either Ma5 or 4/91. Both of those
strains are immunogenic, but while Ma5 alone seems to
stimulate CMI (especially in the URT) more efficiently
the 4/91 strain generates a wider spectrum of immune
system cross-reactivity and higher URT IgA production.
Eventually, the final answer could be that this efficiency
results from additive impact of Ma5 and 4/91 strains on
different levels of both innate and acquired host immune
response.
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Table 2 Infectious bronchitis HI mean antibody titre (log2 base) +/− SD, 21 DPV
Group IBV diagnostic strain
M41 4/91 D3128 Italy O2 D8880 D274 D1466
Control HI titer 2,4b 3,0b 2,0b 2,25a 3,0b 2,0b 2,8 b
SD 0,55 0,00 0,00 0,50 0,71 0,00 0,84
Ma5 HI titer 3,2a, b 3,22b 2,0 b 3,33 a 3,6 a, b 3,0 a, b 4,6 a, b
SD 0,45 0,45 0,00 0,58 0, 55 0,71 1,34
4/91 HI titer 4,25 a 5,42a 3,5 a 3,5 a 4,0 a, b 5,0a 6,8a
SD 0,96 0,55 0,71 0,71 0,71 1,41 1,64
V2 HI titer 3,8a, b 4,2a, b 2,67a, b 2,6 a 4,8a 3,5 a, b 4,5 a, b
SD 0,45 0,00 0,58 0,55 0,45 0,58 1,30
a, b—Mean values in a column with different superscript letters are significantly different (Kruskal-Wallis test, p < 0,05)
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